Global Market Size, Forecast, and Trend Highlights Over 2025-2037
SGLT2 Inhibitors Treatment Market size was valued at USD 6.42 billion in 2024 and is set to exceed USD 21.14 billion by 2037, registering over 9.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of SGLT2 inhibitors treatment is evaluated at USD 7.44 billion.
The increasing prevalence of diabetes has fuelled the demand for innovative products, advanced technologies, and personalized solutions. According to the International Diabetes Federation, nearly 783 million adults will be living with diabetes by the end of 2045.
Government efforts to raise awareness of the disease to help in cure and diagnosis at an earlier stage are anticipated to elevate the market’s growth. Moreover, this is leading to growing awareness among people related to diabetes mellitus, and it’s treatment methods.
SGLT2 Inhibitors Treatment Market: Growth Drivers and Challenges
Growth Drivers
- Excessive Sugar Diet Leads to Incidences of Diabetic Patients- Diabetes is increased by consuming an excessive amount of sugar. In addition, the diabetes diagnostic market is growing at a fast rate due to advances in devices for diagnosis of diabetes such as portable glucometers. Glucometer is a little, portable device that measures the level of blood glucose for people with diabetes. By 2022, sugar consumption in the world is expected to reach around 176 million tons, and it is anticipated that by 2024 about 180.05 million tons will be consumed in the world's trade.
- Growing Medical and R&D Activities- Pharmaceutical companies investing in the research and development of SGLT2 Inhibitors demonstrate their commitment to improving diabetic management and continued advancements in drug development. On average the Food and Drug Administration approved nearly 38 new drugs every year from 2010 to 2019.
- Digital Health and Telemedicine- Leveraging technology, especially in the form of digital health platforms and telemedicine, can overcome geographical and linguistic barriers. However, with the recent emergence of digital therapeutics, helping to bring healthcare services online, this situation is changing to promote the adoption of telemedicine as it is convenient and boosts market growth.
Challenges
- Economic limitations- Patients from the middle-low-income region might lack healthcare insurance or face financial constraints, limiting their ability to afford medical consultations or purchase expensive medications such as SGLT2 inhibitors. The middle low-income region often faces resource constraints, including inadequate healthcare infrastructure, which hinders the dissemination of knowledge about novel treatment like SGLT2.
- Competition from Existing Diabetes Treatment Drug
- Surging Risk of Amputations
SGLT2 Inhibitors Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.6% |
|
Base Year Market Size (2024) |
USD 6.42 billion |
|
Forecast Year Market Size (2037) |
USD 21.14 billion |
|
Regional Scope |
|
SGLT2 Inhibitors Treatment Segmentation
Application (Glucose Dissipation, Blood Transfusion)
The glucose dissipation segment is estimated to hold 56% share of the global SGLT2 inhibitors treatment market during the forecasted timeframe. Due to the advancement in glucose dissipation, the SGLT2 treatment market is addressed the unbeatable growth of 8.6% over the years. In order to decrease high blood glucose, the SGLT2 inhibitors work by a new mechanism to reduce renal tubular glucose reabsorption and thus decrease blood glucose levels without inducing the release of insulin.
End Users (Hospitals, Clinics, Diagnostic Centers)
SGLT2 inhibitors treatment market from the diagnostic centers sector is predicted to show the largest share of 42 % by the end of 2037. The qualified healthcare professionals in diagnostic centers with a growing estimation of 14% per annum, such as endocrinologists or primary care physicians, often diagnose and prescribe SGLT2 inhibitors after thoroughly evaluating a patient's medical history, present health, and needs for diabetic management. Moreover, the rising investment in diagnostic services is further expected to boost the segment’s growth. For instance the National Health Service, spends more than USD 6 billion on more than 90 diagnostic services in a year.
Our in-depth analysis of the global market includes the following segments:
|
Application |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSGLT2 Inhibitor Treatment Industry - Regional Synopsis
North America Market Analysis
North America industry is predicted to account for largest revenue share of 32% by 2037. With the increasing prevalence of obesity and lifestyle changes in the region, chronic diseases are growing on a yearly basis. Approximately 50 % of Americans suffer from at least one chronic disease every year. Additionally, it is predicted that the region's high healthcare spending will spur market expansion. According to data from the World Bank, the area of North America spent 16.415% of its total GDP on healthcare.
Asia Pacific Market Analysis
Asia Pacific region is expected to witness the fastest growth of 8.35% during the forecast period. The factors such as rising disposable income, increasing social organization awareness, improving health care facilities, and more R&D activities are expected to drive the growth of the market in the Asia-pacific region.
Companies Dominating the SGLT2 Inhibitors Treatment Landscape
- Novartis International AG
- Company overview
- Business strategy
- Key product offerings
- Financial performances
- Key performance indicators
- Risk analysis
- Recent development
- Regional presence
- SWOT analysis
- Boehringer Ingelheim GmbH
- Janssen pharmaceuticals
- GRUPO TECNIMEDE
- Unichem Laboratories Ltd.
- Edificio Bluepharma
In the News
- Astellas Pharma Inc., announced that selective SGLT2 inhibitor Suglat Tablets 25mg and 50mg Ipragliflozin L-Proline, “Suglat Tablets”) became available for the indication of type 2 diabetes in the Japanese market today.
- AstraZeneca’s Forxiga (dapagliflozin) was approved in China to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF).
Author Credits: Radhika Pawar
- Report ID: 3972
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
